Análisis De Costo-Efectividad De Dos Formulaciones De Toxina Botulínica Tipo a (TBA) En Colombia Para El Tratamiento De La Parálisis Cerebral Infantil (PCI)

Abstract

Brazilian patients eligible for Relapsing-Remitting Multiple Sclerosis (RRMS) treatment was estimated to be around 7,098, 2,397 and 498 patients (1 st , 2 nd and 3 rd line treatment, respectively) in the first year. Compared to the current scenario, the inclusion of natalizumab in the reimbursement protocol for 2 nd line shows an additional budget through the 5 years consecutively as: 124.9K, 365.7K, 652.3K, 912.8K and 1.0M (USD). It is expected that during the 5-year analysis, the inclusion of natalizumab as 2 nd line will increase the budget for MS by 4% with average cost per MS patient of USD50.60 (USD13.061 vs USD13.112 per patient/year). ConClusions: The estimated budget impact to include natalizumab as a 2 nd line treatment option was USD3.1M in five years (increment of 4.0% of the current budget) for MS treatment.